115 related articles for article (PubMed ID: 25974184)
1. Development and validation of a novel platform-independent metastasis signature in human breast cancer.
Zhao SG; Shilkrut M; Speers C; Liu M; Wilder-Romans K; Lawrence TS; Pierce LJ; Feng FY
PLoS One; 2015; 10(5):e0126631. PubMed ID: 25974184
[TBL] [Abstract][Full Text] [Related]
2. Validation and clinical discovery demonstration of breast cancer data from a real-world data extraction platform.
Nottke A; Alan S; Brimble E; Cardillo AB; Henderson L; Littleford HE; Rojahn S; Sage H; Taylor J; West-Odell L; Berk A
JAMIA Open; 2024 Jul; 7(2):ooae041. PubMed ID: 38766645
[TBL] [Abstract][Full Text] [Related]
3. Modelling circulating tumour cells for personalised survival prediction in metastatic breast cancer.
Ascolani G; Occhipinti A; Liò P
PLoS Comput Biol; 2015 May; 11(5):e1004199. PubMed ID: 25978366
[TBL] [Abstract][Full Text] [Related]
4. Multiple gene aberrations and breast cancer: lessons from super-responders.
Wheler JJ; Atkins JT; Janku F; Moulder SL; Yelensky R; Stephens PJ; Kurzrock R
BMC Cancer; 2015 May; 15():442. PubMed ID: 26021831
[TBL] [Abstract][Full Text] [Related]
5. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
[TBL] [Abstract][Full Text] [Related]
6. Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer.
Begg CB; Orlow I; Zabor EC; Arora A; Sharma A; Seshan VE; Bernstein JL
Cancer Med; 2015 Sep; 4(9):1432-9. PubMed ID: 25974664
[TBL] [Abstract][Full Text] [Related]
7. Integrative clinical genomics of advanced prostate cancer.
Robinson D; Van Allen EM; Wu YM; Schultz N; Lonigro RJ; Mosquera JM; Montgomery B; Taplin ME; Pritchard CC; Attard G; Beltran H; Abida W; Bradley RK; Vinson J; Cao X; Vats P; Kunju LP; Hussain M; Feng FY; Tomlins SA; Cooney KA; Smith DC; Brennan C; Siddiqui J; Mehra R; Chen Y; Rathkopf DE; Morris MJ; Solomon SB; Durack JC; Reuter VE; Gopalan A; Gao J; Loda M; Lis RT; Bowden M; Balk SP; Gaviola G; Sougnez C; Gupta M; Yu EY; Mostaghel EA; Cheng HH; Mulcahy H; True LD; Plymate SR; Dvinge H; Ferraldeschi R; Flohr P; Miranda S; Zafeiriou Z; Tunariu N; Mateo J; Perez-Lopez R; Demichelis F; Robinson BD; Schiffman M; Nanus DM; Tagawa ST; Sigaras A; Eng KW; Elemento O; Sboner A; Heath EI; Scher HI; Pienta KJ; Kantoff P; de Bono JS; Rubin MA; Nelson PS; Garraway LA; Sawyers CL; Chinnaiyan AM
Cell; 2015 May; 161(5):1215-1228. PubMed ID: 26000489
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.
Generali D; Venturini S; Rognoni C; Ciani O; Pusztai L; Loi S; Jerusalem G; Bottini A; Tarricone R
Breast Cancer Res Treat; 2015 Jul; 152(1):95-117. PubMed ID: 26044370
[TBL] [Abstract][Full Text] [Related]
9. Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
McDonnell DP; Wardell SE; Norris JD
J Med Chem; 2015 Jun; 58(12):4883-7. PubMed ID: 26039356
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
[TBL] [Abstract][Full Text] [Related]
12. Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis.
Si W; Huang W; Zheng Y; Yang Y; Liu X; Shan L; Zhou X; Wang Y; Su D; Gao J; Yan R; Han X; Li W; He L; Shi L; Xuan C; Liang J; Sun L; Wang Y; Shang Y
Cancer Cell; 2015 Jun; 27(6):822-36. PubMed ID: 26028330
[TBL] [Abstract][Full Text] [Related]
13. Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival.
Grosse-Wilde A; Fouquier d'Hérouël A; McIntosh E; Ertaylan G; Skupin A; Kuestner RE; del Sol A; Walters KA; Huang S
PLoS One; 2015; 10(5):e0126522. PubMed ID: 26020648
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Rocca A; Farolfi A; Maltoni R; Carretta E; Melegari E; Ferrario C; Cecconetto L; Sarti S; Schirone A; Fedeli A; Andreis D; Pietri E; Ibrahim T; Montalto E; Amadori D
Breast Cancer Res Treat; 2015 Jul; 152(1):57-65. PubMed ID: 26012644
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.
Hart CD; Migliaccio I; Malorni L; Guarducci C; Biganzoli L; Di Leo A
Nat Rev Clin Oncol; 2015 Sep; 12(9):541-52. PubMed ID: 26011489
[TBL] [Abstract][Full Text] [Related]
16. Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs.
Willis S; De P; Dey N; Long B; Young B; Sparano JA; Wang V; Davidson NE; Leyland-Jones BR
Meta Gene; 2015 Jun; 4():129-41. PubMed ID: 26005638
[TBL] [Abstract][Full Text] [Related]
17. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.
Ng CK; Martelotto LG; Gauthier A; Wen HC; Piscuoglio S; Lim RS; Cowell CF; Wilkerson PM; Wai P; Rodrigues DN; Arnould L; Geyer FC; Bromberg SE; Lacroix-Triki M; Penault-Llorca F; Giard S; Sastre-Garau X; Natrajan R; Norton L; Cottu PH; Weigelt B; Vincent-Salomon A; Reis-Filho JS
Genome Biol; 2015 May; 16(1):107. PubMed ID: 25994018
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
Yu Q; Zhu Z; Liu Y; Zhang J; Li K
PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
[TBL] [Abstract][Full Text] [Related]
19. Early detection of breast cancer using total biochemical analysis of peripheral blood components: a preliminary study.
Zelig U; Barlev E; Bar O; Gross I; Flomen F; Mordechai S; Kapelushnik J; Nathan I; Kashtan H; Wasserberg N; Madhala-Givon O
BMC Cancer; 2015 May; 15():408. PubMed ID: 25975566
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
